Methods and Compounds for Promoting Vessel Regression

ABSTRACT

The present invention relates, at least in part, to methods and compositions for treating and diagnosing disorders associated with neovascularization, and methods for identifying targets and compositions used in treating and diagnosing such disorders.

CLAIM OF PRIORITY

This application is a continuation of U.S. application Ser. No. 13/007,202, which was filed on Jan. 14, 2011, which is a continuation of U.S. application Ser. No. 11/363,402, which was filed on Feb. 24, 2006, which claims the benefit under 35 USC §119(e) of U.S. Provisional Patent Application Ser. Nos. 60/656,168, filed on Feb. 24, 2005, and 60/719,998, filed on Sep. 23, 2005. The entire contents of each of these applications is hereby incorporated by reference.

TECHNICAL FIELD

This invention relates to methods and compounds for promoting vessel regression, e.g., to treat disorders associated with neovascularization.

BACKGROUND

The hyaloid vascular system (HVS) is a transiently existing network of capillaries that function to nourish the immature lens and primary vitreous of the developing eye. The hyaloid artery (HA) runs from the back of the eye to the embryonic lens giving rise to a capillary plexus that surrounds the lens, consisting of the vasa hyaloidea propria (VHP), the tunica vasculosa lentis (TVL) and the pupillary membrane (PM). The HVS provides a useful system to investigate physiologically relevant angiogenesis and vascular remodeling processes.

The first elements of the human hyaloid vasculature to undergo regression are the VHP, followed by the TVL, PM and lastly the main hyaloid trunk, commencing at 12 weeks of gestation (WG) and culminating in the involution of the entire hyaloid by 35-36 WG (Mann I. The Development of the Human Eye. Pp 201-32. Grune & Stratton Inc: New York, 1964). In humans, failure of the hyaloid vascular system to regress can lead to a condition known as persistent hyperplastic primary vitreous (PHPV), which can result in permanent blindness if left untreated.

Mitchell and coworkers showed that in mice the hyaloid vascular system is first recognized at embryonic day 10.5 (E10.5), is complete by E13.5 and regresses postnatally prior to eyelid opening (Mitchell C A, et al., Dev. Dyn. 213(3):322-33 (1998)). During mouse development, the longer branches of the TVL and the longer hyaloid vessels are removed by post-gestational day 16 (P16) (Mitchell C A, et al., Dev. Dyn. 213(3):322-33 (1998)). Ito et al. presented partially similar results, showing that the PM had completely disappeared by P16, and the VHP had disappeared between P12 and P16, but the TVL and the hyaloid artery remained even at P16 (Ito and Yoshioka, Anat. Embryol. (Berl). 200(4):403-11 (1999)). Smith showed a gradual disappearance of the TVL and hyaloid artery from P14 to P30 (Smith, Systematic evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Pp 45-63. Sunders, 2002).

Previous hypotheses of the mechanism of regression of the hyaloid vascular system included the following:

A. The reduction or the cessation of the blood flow into the HVS was thought to be one of the major triggering factors of the regression in these vessels. A change in the blood flow distribution (Bischoff et al., Graefes Arch. Clin. Exp. Ophthalmol. 220 (6):257-63 (1983)) and competition between the blood vessels in the retina and the lens for the blood flow can lead to the degeneration of the HVS when the retinal blood vessels become larger and require more nutrients.

B. Vascular obstruction, physical vascular stretching, localized circulatory stasis, and arterial vasoconstriction were regarded as triggering factors of the regression of the HVS (Jack, Am. J. Ophthalmol. 74 (2):261-72 (1972); Latker and Kuwabara, Invest. Ophthalmol. Vis. Sci. 21 (5):689-99 (1981)). The regression occurs first in those vessels that were hemodynamically disadvantaged and consequently had less blood flow.

C. Meeson et al. have shown that the occurrence of apoptosis in the PM strictly correlated to the flow status; as the flow decreased the appearance of apoptosis in capillaries increased (Meeson et al., Development. 122(12):3929-38 (1996)). The same correlation may exist in the hyaloid vascular system. As the main role of the HVS is supposed to be to nourish the retina before the maturation of retinal vessels, the HVS may regress after the completion of these vessels.

D. Macrophages may also be required in the programmed regression of the PM and the HVS (Lang and Bishop, Cell. 13; 74 (3):453-62 (1993); Lang et al., Development. 120 (12):3395-403 (1994); Diez-Roux and Lang, Development. 124 (18):3633-8 (1997)).

E. The anti-angiogenic ability of the vitreous humor and vitreous extracts may also be important in the regression of the TVL (Preis et al., Am. J. Ophthalmol. 84 (3):323-8 (1977); Felton et al., Arch. Ophthalmol. 97 (9):1710-3 (1979); Lutty et al., Invest. Ophthalmol. Vis. Sci. 24 (1):52-6 (1983); Taylor and Weiss, Biochem Biophys Res Commun. 133 (3):911-6 (1985); Zhu et al., Aust. N. Z. J. Ophthalmol. 25 Suppl 1:S57-60 (1997); Ramesh et al., Br. J. Ophthalmol. 88 (5):697-702 (2004)). Hyalocytes play also a role in the regression of the TVL (McMenamin et al., Invest. Ophthalmol. V is Sci. 43 (7):2076-82 (2002)). Lutty et al. have demonstrated that the hyalocytes produce and process transforming growth factor-β (TGF-β) which may inhibit is the proliferation of the vascular endothelial cells in this system (Lutty et al., Invest. Ophthalmol. Vis. Sci. 34 (3):477-87 (1993)).

F. Several survival factors may protect cells from apoptosis, including fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). A reduction in levels of these growth factors below a critical threshold may lead to the induction of an apoptotic program.

The role of VEGF in the maintenance of the VHP is not clear. Feenay et al. demonstrated that the TVL degeneration was unexpectedly uninfluenced by treatment with a VEGF A antibody, suggesting that programmed regression is independent of VEGF A, or that the development and maturation of the lens had gone beyond the point of the plasticity and susceptibility to certain growth factors (Feeney et al., Invest. Ophthalmol. Vis. Sci. 44 (2):839-47 (2003)).

SUMMARY

The present invention is based, at least in part, on the results of proteomic analysis of the mouse lens and vitreous during postnatal development, which identified novel proteins that contribute to regression of the hyaloid system. Among other proteins, two-dimensional electrophoresis and mass spectrometry of the developing mouse lens and vitreous identified activin receptor-like kinase-1 (ALK1) as a differentially expressed protein during HVS regression; immunohistochemical staining demonstrated the localization of ALK1 in the TVL; and overexpression of ALK1 in the cornea resulted in inhibition of bFGF-induced corneal neovascularization in vivo. Activin receptor-like kinase-1 (ALK1) activates Smads1, 5 and 8 which down-regulate VEGF production. In contrast, ALK5 activates Smads2 and 3 which up-regulate VEGF production (Goumans et al., EMBO. J. 21, 1743-1753 (2002)). Expression of ALK1 in blood vessels and mutations of the ALK1 gene in patients with human type II hereditary hemorrhagic telangiectasia, a multi-systemic vascular dysplasia, suggests that ALK1 may play an important role during normal vascular development (Oh et al., Proc Natl Acad Sci USA 97, 2626-2631 (2000)).

Thus, ALK1 polypeptides and nucleic acids are useful compositions and targets for treating disorders associated with neovascularization (NV), and in cancer therapy.

In one aspect, the invention provides methods for treating patients who have a disorder associated with neovascularization, e.g., an ophthalmological disorder associated with neovascularization. The methods include administering to the patient a therapeutically effective amount of an ALK1 polypeptide or nucleic acid composition, e.g., as described herein. The invention further includes therapeutic compositions including the ALK1 polypeptides or nucleic acids described herein, as well as inhibitors and/or agonists thereof, and methods for identifying such compounds.

Ophthalmological disorders associated with neovascularization include eye cancer, age-related macular degeneration, retinopathy of prematurity, corneal graft rejection, glaucoma, diabetic retinopathy, wounds, age-related macular degeneration, herpetic and infectious keratitis, ocular ischemia, neovascular glaucoma, corneal, uveal and iris neovascularization, orbital and eyelid tumors, Stevens Johnson Syndrome, ocular cicatricial pemphigoid, and ocular surface diseases. In some embodiments, the ophthalmological disorder is associated with corneal, retinal, choroidal, uveal, or iris neovascularization. For an ophthalmological disorder, the administering can be, e.g., topical or parenteral administration into the eye, e.g., including, but not limited to, local injection into or near the cornea, retina, vitreous, uvea, orbit, eyelid, conjunctiva, or iris.

In some embodiments, the disorder is cancer, e.g., as described herein.

In some embodiments, the subject is selected on the basis that he or she has a disorder associated with neovascularization as described herein.

In some embodiments, the administering can be, e.g., local or systemic, e.g., parenteral or oral.

In another aspect, the invention provides methods for identifying candidate therapeutic compounds for the treatment of a disorder associated with neovascularization. The methods include obtaining a sample including a cell that is capable of expressing one or more of the genes listed in Tables 1-6; contacting the sample with the test compound; and evaluating levels, expression, or activity of the gene(s) in the sample, e.g., in the cell. Modulation of levels, expression, or activity of the gene(s) in the sample indicates that the test compound is a candidate therapeutic compound for the treatment of a disorder associated with neovascularization. The levels, expression, or activity of the gene in the sample can be evaluated by methods known in the art, e.g., enzyme assays, immunoassays, high-throughput DNA, RNA, or protein assays, etc. In some embodiments, the gene is ALK1.

In some embodiments, the method further includes administering the candidate therapeutic compound to an animal model of a disorder associated with neovascularization, and monitoring the animal model for an effect of the candidate therapeutic compound on a parameter of the disorder, e.g., vascularisation, in the animal. A candidate therapeutic compound that causes an improvement in the parameter in the animal model is a candidate therapeutic agent for the treatment of the disorder. In some embodiments, the methods further include administering the candidate therapeutic agent to a subject having the disorder, e.g., a subject in a clinical trial, and monitoring a parameter of the disorder in the subject. A candidate therapeutic agent that improves the parameter in the subject is a therapeutic agent for the treatment of the disorder. In some embodiments, the parameter is visual acuity. In some embodiments, the methods include administering a therapeutically effective amount of the therapeutic agent to a subject in need of treatment for the disorder, thereby treating the disorder.

In a further aspect, the invention provides methods for identifying candidate compounds, e.g., naturally-occurring compounds, e.g., a polypeptide or biologically active fragment thereof, for the treatment of a disorder associated with neovascularization. The methods include providing a sample including:

-   -   (i) cells from a subject, e.g., a human subject, having a         disorder associated with blood vessel regression, e.g.,         retinopathy of prematurity, persistent hyperplastic primary         vitreous (PHPV), or retrolental fibroplasia; or     -   (ii) cells from a subject, e.g., a human subject, in a stage of         development that is associated with vessel regression, e.g., a         stage in the development of the hyaloid vascular system;         determining the expression levels of proteins, e.g., one or         more, e.g., 2, 3, 5, 10, 15, 20, 25, 30, 50 or 100, of the of         the proteins listed in Tables 1-6, in the sample; and comparing         the expression levels to a reference, e.g., a sample from an         unaffected subject or a subject at a different stage of         development associated with blood vessel regression, e.g., a         different stage the development of the hyaloid vascular system.         A compound that is differentially expressed, e.g., significantly         differentially expressed, is a candidate compound for the         treatment of a disorder associated with neovascularization.

In another aspect, the invention includes methods for treating a disorder associated with neovascularization, e.g., an ophthalmological disorder associated with neovascularization as described herein, in a subject by administering a therapeutically effective amount of a therapeutic composition including an activin receptor-like kinase-1 (ALK1) polynucleotide or polypeptide, or an active fragment thereof.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-C. Proteomic analysis of proteins from the lens and vitreous of P1 and P16 mice. The merged image (1A) represents the warped image between P1 (1B) and P16 (1C) obtained with Phoretix 2D evolution software. The proteins excised from 2-D gel (P16) for analysis and identification by mass spectrometry are identified with numbers 1-20 (1C).

FIGS. 2A-Q. bFGF-pellet induced corneal neovascularization (NV) is inhibited by naked ALK1 DNA injection in vivo. No-pellet controls are shown in 3A-H: Injection of naked DNA [ALK1 (2E-H) and vector only (2A-D)] did not induce corneal NV. The vector plus pellet positive controls are shown in 3I-L: development of NV in the corneal stroma was evident by day 4 (2J); new vessels continued to grow in the direction of the pellet on days 7 and 14. None of the mice in the ALK1 and pellet groups (2M-P) showed development of corneal NV on days 1, 4, 7, and 14 after pellet implantation. Asterisk (*) indicates pellet implantation. The area of corneal NV of the four groups at days 1-14 is shown (2Q).

FIG. 3A-B are the amino acid (3A; SEQ ID NO:1) and nucleic acid (3B; SEQ ID NO:2) sequences of human ALK1.

DETAILED DESCRIPTION

A proteomic approach was used to decipher the biochemical events coexistent with the time points of the progressive regression of the HVS. Reproducible two-dimensional electrophoresis (2-DE) maps were used to study modifications of the protein expression profiles occurring in the mouse lens and vitreous at various stages of the regression of the hyaloid capillaries network. The identity of separated and differentially expressed proteins was confirmed by mass spectrometry (Thermo Electron's Finnigan LCQ Deca XP Plus™ Electrospray ionization (ESI) mass spectrometer).

In particular, attention was focused on the differential protein expression between postnatal day 1 and postnatal day 16. Optical microscopy and hematoxylin-eosin staining studies showed the progressive regression of the hyaloid vascular system of the mouse eye between P1, in which PM, TVL and HV are present and P16, in which these mature capillary structures²¹ are almost completely regressed. Proteins identified in these screens are targets for therapeutic intervention for the treatment of various disorders associated with neovascularization. Tables 1-6 list proteins which are expected to play a role in vascularisation, inhibition of blood vessel regression, both in the HVS and in other systems, e.g., including pathophysiological processes, and are thus useful in the treatment of disorders associated with neovascularization, as described herein.

Activin Receptor-Like Kinase-1 (ALK1)

TGF-β is a potent inhibitor of vascular endothelial cell proliferation (Lutty et al., (1993), supra). It regulates endothelial proliferation via two receptor/Smad (mother against decapentaplegic) pathways. After ligand binding and activation of Type I receptors, signals are transduced from the membrane to the nucleus via Smads (Seki et al., Circ Res 93, 682-689 (2003)). Type I receptors recruit and phosphorylate Smads, such as Smads2 and 3 by the TβRI/ALK5 type I receptor in response to TGF-β, and Smads1, 5 and 8 by the BMP (bone morphogenetic protein) type I receptors (Feng, Ann. Rev. Cell. Dev. Biol. 659-693 (2005)).

ALK1 is one of the seven Type I receptors for the TGF-β family of proteins (ten Dijke et al., Science 264, 101-104 (1994); GenelD: 94; GenBank Accession Nos. NM_(—)000020.1 (nucleic acid) and NP_(—)000011.1 (polypeptide)). ALK1 expression has been detected in endothelial cells of highly vascularized tissues (lungs and placenta) (Panchenko et al., Am. J. Physiol. 270, L547-L558 (1996)), normal and neoplastic pituitary cells (Alexander et al., J. Clin. Endocrinol. Metab. 81, 783-790 (1996)), anaplastic large cell lymphoma (Sadahira et al., Pathol. Res. Pract. 195, 657-661 (1999)), inflammatory myofibroblastic tumor (Coffin et al., Mod. Pathol. 14, 569-576 (2001)) and central nervous system cells (Pulford et al., Blood 89, 1394-1404 (1997)). ALK1 transduces the TGF-β1 signal by phosphorylating Smad1, Smad5 or Smad8 (Goumans, et al., EMBO. J. 21, 1743-1753 (2002); Oh et al., Proc. Natl. Acad. Sci. U.S.A. 97, 2626-2631 (2000)). In contrast, ALK5 activates Smads2 and 3 which up-regulate VEGF production (Goumans et al., EMBO J. 21, 1743-1753 (2002)). Upon phosphorylation by the receptors, Smad complexes translocate into the nucleus, where they cooperate with sequence-specific transcription factors at the promoter DNA to regulate gene expression (Feng and Derynck, Annu Rev. Cell. Dev. Biol. 659-693 (2005)). This functional and physical interaction confer both specificity and complexity in transcriptional responses to TGF-β family ligands (Id.).

Mutations of the ALK1 or endoglin genes have been linked to the human vascular disorder Hereditary Hemorrhagic Telangiectasia (HHT) (Johnson et al., Nat. Genet. 13, 189-195 (1996); McAllister et al., Nat. Genet. 8, 345-351 (1994)). This is an autosomal-dominant disorder, also known as Osler-Rendu-Weber syndrome, characterized by the age-dependent development of focal arteriovenous malformations and telangiectases (Srinivasan et al., Hum. Mol. Genet. 12, 473-482 (2003)). HHT type 2 is caused by loss of function of the activin receptor-like kinase 1 (ACVRL1 or ALK1) (Id.). The disease is characterized by dilated, thin-walled, vascular anomalies of the skin and mucous membranes and recurrent epistaxis. In the literature, abnormal eye disorders have been documented in 45-65% of patients with HHT, with the most common lesions being conjunctival telangiectasias (Brant et al., Am. J. Ophthalmol. 107, 642-646 (1989); Vase and Vase, Acta. Ophthalmol. Copen. 57, 1084-1090 (1979)). Retinal arteriovenous malformations, retinal telangiectasia and choroidal haemorrhage during intraocular surgery have also been noted (Brant et al., (1989) supra; Mahmoud et al., Am. J. Ophthalmol. 133, 282-284 (2002)).

The sequences of the human ALK1 polypeptide (SEQ ID NO:1) and polynucleotide (SEQ ID NO:2) are shown in FIG. 3. Active fragments thereof include, e.g., amino acids 22-503 of SEQ ID NO:1, or nucleotides 346-1791 of SEQ ID NO:2. Active fragments can also include the GS motif, i.e., amino acids 173-202 of SEQ ID NO:1; the Serine/Threonine protein kinases, catalytic domain, i.e., amino acids 204-487 of SEQ ID NO:1; and/or the Activin types I and II receptor domain, i.e., amino acids 19-103 of SEQ ID NO:1. An active fragment retains the ability to block bFGF-induced neovascularization. Homologs of the human ALK1 in other species are known, e.g., for rat, GenBank Accession No. NM_(—)022441.1; for mouse, NM_(—)009612.1

Pharmaceutical Compositions and Methods of Administration

The polypeptides listed in Tables 1-6, and nucleic acid molecules encoding or inhibiting them, can be incorporated into pharmaceutical compositions as active ingredients. In some embodiments, the pharmaceutical compositions include a human ALK1 polypeptide (e.g., SEQ ID NO:1) or polynucleotide (e.g., SEQ ID NO:2), or an active fragment thereof. In general, it will be preferable to match the composition to the species that is being treated; thus, for example, when treating experimental animals such as mice other species can be used, e.g., from rats or mice.

Pharmaceutical compositions typically include the active ingredient and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition is typically formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

In some embodiments, the composition is especially adapted for administration into or around the eye. For example, a composition can be adapted to be used as eye drops, or injected into the eye, e.g., using peribulbar or intravitreal injection. Such compositions should be sterile and substantially endotoxin-free, and within an acceptable range of pH. Certain preservatives are thought not to be good for the eye, so that in some embodiments a non-preserved formulation is used. Formulation of eye medications is known in the art, see, e.g., Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach, Reddy, Ed. (CRC Press 1995); Kaur and Kanwar, Drug Dev Ind Pharm. 2002 May; 28(5):473-93; Clinical Ocular Pharmacology, Bartlett et al. (Butterworth-Heinemann; 4th edition (Mar. 15, 2001)); and Ophthalmic Drug Delivery Systems (Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs), Mitra (Marcel Dekker; 2nd Rev&Ex edition (Mar. 1, 2003)).

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Pat. No. 6,468,798.

Administration of a therapeutic composition described herein can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

Compositions comprising nucleic acid compounds can also be administered by any method suitable for administration of nucleic acid agents. These methods include gene guns, bio injectors, and skin patches as well as needle-free methods such as the micro-particle DNA vaccine technology disclosed in U.S. Pat. No. 6,194,389, and the mammalian transdermal needle-free vaccination with powder-form vaccine as disclosed in U.S. Pat. No. 6,168,587. Additionally, intranasal delivery is possible, as described in, inter alia, Hamajima et al., Clin. Immunol. Immunopathol., 88(2), 205-10 (1998). Liposomes (e.g., as described in U.S. Pat. No. 6,472,375) and microencapsulation can also be used. Biodegradable targetable microparticle delivery systems can also be used (e.g., as described in U.S. Pat. No. 6,471,996). In some embodiments, the nucleic acid compounds comprise naked DNA, and are administered locally by injection, e.g., as described herein.

In some embodiments, the compositions are prepared with carriers that will protect the active ingredient against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using standard techniques. The materials can also be obtained commercially, e.g., from Alza Corporation or Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

Dosage, toxicity and therapeutic efficacy of the compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

An “effective amount” is an amount sufficient to effect beneficial or desired results. For example, a therapeutic amount is one that achieves a desired therapeutic effect. This amount can be the same or different from a prophylactically effective amount, which is an amount necessary to prevent onset of disease or disease symptoms. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a composition depends on the composition selected. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the compositions of the invention can include a single treatment or a series of treatments.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Nucleic Acids for Expression

The therapeutic compositions described herein can include nucleic acid molecules encoding a selected protein, e.g., a protein listed in one of Tables 1-6, e.g., ALK1; these are useful, e.g., where an increase in the expression and/or activity of a selected protein is desirable. Nucleic acid molecules comprising expression constructs can be used, e.g., for in vivo or in vitro expression of a selected protein. In some embodiments, expression can be restricted to a particular cell types so as to reconstitute the function of the selected protein in a cell, e.g., a cell in which that polypeptide is misexpressed, or in which expression of that polypeptide would produce a therapeutic benefit.

A nucleic acid encoding the selected protein can be inserted in an expression vector, to make an expression construct. A number of suitable vectors are known in the art, e.g., viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, adenovirus-derived vectors, or recombinant bacterial or eukaryotic plasmids. For example, the expression construct can include: a coding region; a promoter sequence, e.g., a promoter sequence that restricts expression to a selected cell type, a conditional promoter, or a strong general promoter; an enhancer sequence; untranslated regulatory sequences, e.g., a 5′ untranslated region (UTR), a 3′UTR; a polyadenylation site; and/or an insulator sequence. Such sequences are known in the art, and the skilled artisan would be able to select suitable sequences. See, e.g., Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard laboratory manuals.

Expression constructs can be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the component gene to cells in vivo. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (e.g., Lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO₄ precipitation. In some embodiments, the nucleic acid is applied “naked” to a cell, i.e., is applied in a simple buffer without the use of any additional agents to enhance uptake. See, e.g., Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals.

In clinical settings, the nucleic acids can be introduced into a subject by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by a targeted gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Pat. No. 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) PNAS 91: 3054-3057).

Inhibitory Nucleic Acid Molecules

The therapeutic compositions described herein can include inhibitory nucleic acid molecules that are targeted to a selected target RNA encoding a protein listed in one of Tables 1-6, e.g., antisense, siRNA, ribozymes, and aptamers; these are useful, e.g., where a decrease in the expression and/or activity of a target protein is desirable. Based upon sequences known in the art, one of skill in the art can easily choose and synthesize any of a number of appropriate inhibitory nucleic acid molecules for use in accordance with the present invention. For example, a “gene walk” comprising a series of oligonucleotides of 15-30 nucleotides spanning the length of a target nucleic acid can be prepared, followed by testing for inhibition of target gene expression, to provide an antisense sequence. Optionally, gaps of 5-10 nucleotides can be left between the oligonucleotides to reduce the number of oligonucleotides synthesized and tested. Similar methods can be used to generate siRNAs, aptamers, and ribozymes

siRNA Molecules

RNAi is a process whereby double-stranded RNA (dsRNA, also referred to herein as si RNAs or ds siRNAs, for double-stranded small interfering RNAs,) induces the sequence-specific degradation of homologous mRNA in animals and plant cells (Hutvagner and Zamore, Curr. Opin. Genet. Dev.:12, 225-232 (2002); Sharp, Genes Dev., 15:485-490 (2001)). In mammalian cells, RNAi can be triggered by 21-nucleotide (nt) duplexes of small interfering RNA (siRNA) (Chiu et al., Mol. Cell. 10:549-561 (2002); Elbashir et al., Nature 411:494-498 (2001)), or by micro-RNAs (miRNA), functional small-hairpin RNA (shRNA), or other dsRNAs which are expressed in vivo using DNA templates with RNA polymerase III promoters (Zeng et al., Mol. Cell. 9:1327-1333 (2002); Paddison et al., Genes Dev. 16:948-958 (2002); Lee et al., Nature Biotechnol. 20:500-505 (2002); Paul et al., Nature Biotechnol. 20:505-508 (2002); Tuschl, T., Nature Biotechnol. 20:440-448 (2002); Yu et al., Proc. Natl. Acad. Sci. USA 99(9):6047-6052 (2002); McManus et al., RNA 8:842-850 (2002); Sui et al., Proc. Natl. Acad. Sci. USA 99(6):5515-5520 (2002).)

The nucleic acid molecules or constructs can include dsRNA molecules comprising 16-30, e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more, e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched nucleotide(s), to a target region in the mRNA, and the other strand is complementary to the first strand. The dsRNA molecules can be chemically synthesized, or can transcribed be in vitro from a DNA template, or in vivo from, e.g., shRNA. The dsRNA molecules can be designed using any method known in the art; a number of algorithms are known, and are commercially available. Gene walk methods can be used to optimize the inhibitory activity of the siRNA.

The inhibitory nucleic acid compositions can include both siRNA and modified siRNA derivatives, e.g., siRNAs modified to alter a property such as the pharmacokinetics of the composition, for example, to increase half-life in the body, as well as engineered RNAi precursors.

siRNAs can be delivered into cells by methods known in the art, e.g., cationic liposome transfection and electroporation. siRNA duplexes can be expressed within cells from engineered RNAi precursors, e.g., recombinant DNA constructs using mammalian Pol III promoter systems (e.g., H1 or U6/snRNA promoter systems (Tuschl (2002), supra) capable of expressing functional double-stranded siRNAs; (Bagella et al., J. Cell. Physiol. 177:206-213 (1998); Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al. (2002), supra; Sui et al. (2002), supra). Transcriptional termination by RNA Pol III occurs at runs of four consecutive T residues in the DNA template, providing a mechanism to end the siRNA transcript at a specific sequence. The siRNA is complementary to the sequence of the target gene in 5′-3′ and 3′-5′ orientations, and the two strands of the siRNA can be expressed in the same construct or in separate constructs. Hairpin siRNAs, driven by H1 or U6 snRNA promoter and expressed in cells, can inhibit target gene expression (Bagella et al. (1998), supra; Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al. (2002), supra; Sui et al. (2002) supra). Constructs containing siRNA sequence under the control of T7 promoter also make functional siRNAs when cotransfected into the cells with a vector expression T7 RNA polymerase (Jacque (2002), supra).

Antisense

An “antisense” nucleic acid can include a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to a TEF mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand of a target sequence, or to only a portion thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence (e.g., the 5′ and 3′ untranslated regions).

An antisense nucleic acid can be designed such that it is complementary to the entire coding region of a target mRNA, but can also be an oligonucleotide that is antisense to only a portion of the coding or noncoding region of the target mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the target mRNA, e.g., between the −10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length.

An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. The antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

In some embodiments, the antisense nucleic acid molecule is an V-anomeric nucleic acid molecule. An V-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual (3-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids. Res. 15:6625-6641 (1987)). The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. Nucleic Acids Res. 15:6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al. FEBS Lett., 215:327-330 (1987)).

In some embodiments, the antisense nucleic acid is a morpholino oligonucleotide (see, e.g., Heasman, Dev. Biol. 243:209-14 (2002); Iversen, Curr. Opin. Mol. Ther. 3:235-8 (2001); Summerton, Biochim. Biophys. Acta. 1489:141-58 (1999).

Target gene expression can be inhibited by targeting nucleotide sequences complementary to a regulatory region (e.g., promoters and/or enhancers) to form triple helical structures that prevent transcription of the SptS gene in target cells. See generally, Helene, Anticancer Drug Des. 6:569-84 (1991); Helene, Ann. N.Y. Acad. Sci. 660:27-36 (1992); and Maher, Bioassays 14:807-15 (1992). The potential sequences that can be targeted for triple helix formation can be increased by creating a so called “switchback” nucleic acid molecule. Switchback molecules are synthesized in an alternating 5′-3′,3′-5′ manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

Ribozymes

Ribozymes are a type of RNA that can be engineered to enzymatically cleave and inactivate other RNA targets in a specific, sequence-dependent fashion. By cleaving the target RNA, ribozymes inhibit translation, thus preventing the expression of the target gene. Ribozymes can be chemically synthesized in the laboratory and structurally modified to increase their stability and catalytic activity using methods known in the art. Alternatively, ribozyme genes can be introduced into cells through gene-delivery mechanisms known in the art. A ribozyme having specificity for a target nucleic acid can include one or more sequences complementary to the nucleotide sequence of a cDNA encoding a protein described herein, and a sequence having known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach Nature 334:585-591 (1988)). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a target mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, a target mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak, Science 261:1411-1418 (1993).

Administration of Nucleic Acid Molecules

The nucleic acid molecules described herein can be administered to a subject (e.g., by direct injection at a tissue site), or generated in situ. For example, inhibitory nucleic acid molecules can be administered such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a target protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. Nucleic acid molecules that encode an active agent are generally administered such that they enter a cell and are expressed therein.

In some embodiments, the nucleic acid molecules can be administered selectively, e.g., by local injection, or modified to target selected cells (e.g., by the use of a tissue-specific promoter) and then administered systemically. For systemic administration, nucleic acid molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the nucleic acid nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The nucleic acid nucleic acid molecules can also be delivered to cells using vectors known in the art, e.g., as described herein. To achieve sufficient intracellular concentrations of the inhibitory nucleic acid molecules, vector constructs in which the inhibitory nucleic acid nucleic acid molecule is placed under the control of a promoter, e.g., a strong promoter can be used. Methods for creating suitable vectors, and choosing promoters, are known in the art.

Methods of Treatment

The polypeptides and nucleic acids described herein, e.g., ALK1 polypeptides (e.g., SEQ ID NO:1) or polynucleotides (e.g., SEQ ID NO:2), and active fragments thereof, are useful in the treatment of disorders associated with neovascularization, i.e., abnormal angiogenic processes, e.g., disorders in the formation of blood vessels. Typically, the disorder will stem from overformation of blood vessels, or formation of blood vessels in an unwanted area, e.g., in the avascular regions of the eye, e.g., retinopathies, or in a tumor, e.g., a cancerous or benign tumor. For example, the ophthalmological disorder can be age-related macular degeneration, where new blood vessels grow under the retina, or diabetic retinopathy, where abnormal vessels grow on top of the retina. Other ophthalmological disorders include retinopathy of prematurity, corneal graft rejection, glaucoma, herpetic and infectious keratitis, ocular ischemia, neovascular glaucoma, corneal, uveal and iris neovascularization, orbital and eyelid tumors, Stevens Johnson Syndrome, ocular cicatricial pemphigoid, wounds, and ocular surface diseases. The disorder can be characterized by, for example, corneal, retinal, choroidal, uveal, or iris neovascularization

The disorder may stem from the formation of blood vessels that deliver blood to a tissue, e.g., a primary or metastatic cancerous or benign tumors, e.g., cancer. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.

As used herein, the terms “cancer,” “hyperproliferative,” and “neoplastic” refer to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair; thus, the methods include administration of a compound identified by a method described herein to maintain avascularity during wound healing. In this embodiment, the ophthalmological disorder is a wound, including both accidental as well as intentional wounds (e.g., surgical wounds).

In some embodiments, the ophthalmological disorder is a cancer of the eye, e.g., eyelid tumors, e.g., malignant eye lid tumors, benign eye lid tumors, basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma; conjunctival tumors, e.g., pigmented conjunctival tumors, melanoma and primary acquired melanosis with atypia, squamous conjunctival neoplasia, conjunctival lymphoma, and Kaposi's Sarcoma; iris tumors, e.g., iris melanoma, iris pigment epithelial cyst, anterior uveal metastasis, and pearl cyst of the iris; infiltrative intraocular tumors, e.g., multiple myeloma, lymphoma, and leukemia; choroidal tumors, e.g., choroidal melanoma, choroidal metastasis, choroidal nevus, choroidal hemangioma, choroidal osteoma, and Nevus of Ota; retinal tumors, e.g., retinoblastoma, retinal pigment epithelial tumors, retinal pigment epithelial hypertrophy, von Hippel angioma; optic nerve tumors, e.g., melanocytoma, melanoma, meningioma, circumpapillary metastasis; orbital tumors, e.g., lymphangioma, cavernous hemangioma, meningioma, mucocele, rhabdomyosarcoma, orbital pseudotumor, adenoid cystic carcinoma, periocular hemangioma of childhood; cancers of the ocular adnexa, e.g., lacrimal gland carcinomas such as adenoid cystic carcinoma and mucoepidermal epithelioma; and metastatic ocular tumors, e.g., metastatic choroidal melanoma, and metastatic retinoblastoma.

As used in this context, to “treat” means to ameliorate at least one symptom associated with abnormal angiogenesis as well as reduce neovascularization. For the treatment of cancers and solid tumors, to “treat” includes inhibition of the growth of blood vessels resulting in a lack of nutrients for the tumors and/or cancer cells needed by the tumor for its growth. Tumors and growths will decrease in size and possibly disappear. Administration of a therapeutically effective amount of a composition for the treatment of arthritic conditions will result in decreased blood vessel formation in cartilage, specifically joints, resulting in increased mobility and flexibility in these regions. In ophthalmologic conditions, administration of a therapeutically effective amount of a composition described herein will reduce the formation of extraneous blood vessels in the retina, resulting in unobstructed or less obstructed vision. In the treatment of disorders such as cancer, administration of a therapeutically effective amount of a composition described herein will inhibit the growth and/or further formation of blood vessels, thereby inhibiting the formation of any lesions and/or tumors that arise.

Methods of Screening

The invention includes methods for screening test compounds, e.g., polypeptides, polynucleotides, inorganic or organic large or small molecule test compounds, to identify agents useful in the treatment of disorders associated with neovascularization, e.g., as described herein.

As used herein, “small molecules” refers to small organic or inorganic molecules of molecular weight below about 3,000 Daltons. In general, small molecules useful for the invention have a molecular weight of less than 3,000 Daltons (Da). The small molecules can be, e.g., from at least about 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).

The test compounds can be natural products or members of a combinatorial chemistry library. A set of diverse molecules can be used to cover a variety of functions such as charge, aromaticity, hydrogen bonding, flexibility, size, length of side chain, hydrophobicity, and rigidity. Combinatorial techniques suitable for synthesizing small molecules are known in the art, e.g., as exemplified by Obrecht and Villalgordo, Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries, Pergamon-Elsevier Science Limited (1998), and include those such as the “split and pool” or “parallel” synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, Curr. Opin. Chem. Bio. 1:60-6 (1997)). In addition, a number of libraries, e.g., small molecule libraries, are commercially available. A number of suitable small molecule test compounds are listed in U.S. Pat. No. 6,503,713, incorporated herein by reference in its entirety.

Libraries screened using the methods of the present invention can comprise a variety of types of test compounds. A given library can comprise a set of structurally related or unrelated test compounds. In some embodiments, the test compounds are peptides or peptidomimetic molecules. In some embodiments, the test compounds are nucleic acids, e.g., antisense, RNAi, or aptamers.

In some embodiments, the test compounds and libraries thereof can be obtained by systematically altering the structure of a first test compound, e.g., a first test compound that is structurally similar to a known natural binding partner of the target polypeptide, or a first small molecule identified as capable of binding the target polypeptide, e.g., using methods known in the art or the methods described herein, and correlating that structure to a resulting biological activity, e.g., a structure-activity relationship study. As one of skill in the art will appreciate, there are a variety of standard methods for creating such a structure-activity relationship. Thus, in some instances, the work may be largely empirical, and in others, the three-dimensional structure of an endogenous polypeptide or portion thereof can be used as a starting point for the rational design of a small molecule compound or compounds. For example, in one embodiment, a general library of small molecules is screened, e.g., using the methods described herein.

In some embodiments, a test compound is applied to a test sample, e.g., a cell or living tissue or organ, e.g., an eye, and one or more effects of the test compound is evaluated. In a cultured or primary cell for example, the ability of the test compound to modulate expression of one or more of the proteins listed in Tables 1-6 can be evaluated. In the eye, for example, the ability of the test compounds to modulate expression of one or more of the proteins listed in Tables 1-6 can be evaluated. Methods for evaluating each of these effects are known in the art. For example, ability to modulate expression of a protein can be evaluated at the gene or protein level, e.g., using quantitative PCR or immunoassay methods. In some embodiments, high throughput methods, e.g., protein or gene chips as are known in the art (see, e.g., Ch. 12, Genomics, in Griffiths et al., Eds., Modern Genetic Analysis, 1999, W. H. Freeman and Company; Ekins and Chu, Trends in Biotechnology, 1999, 17:217-218; MacBeath and Schreiber, Science 2000, 289(5485):1760-1763; Simpson, Proteins and Proteomics: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 2002; Hardiman, Microarrays Methods and Applications: Nuts & Bolts, DNA Press, 2003), can be used to detect an effect on two, three, four, five or more of the proteins listed in Tables 1-6.

Compounds identified as “hits” (e.g., test compounds that demonstrate an ability to modulate, i.e., cause an increase or decrease in levels, expression, or activity, of one or more of the proteins listed in Tables 1-6) in the first screen can be selected and systematically altered, e.g., using rational design, to optimize binding affinity, avidity, specificity, or other parameter. Such optimization can also be screened for using the methods described herein. Thus, in one embodiment, the invention includes screening a first library of small molecules using a method known in the art and/or described herein, identifying one or more hits in that library, subjecting those hits to systematic structural alteration to create a second libraries of compounds structurally related to the hit, and screening the second library using the methods described herein.

Small molecules identified as hits can be considered candidate therapeutic compounds, useful in treating disorders associated with neovascularization, as described herein. A variety of techniques useful for determining the structures of “hits” can be used in the methods described herein, e.g., NMR, mass spectrometry, gas chromatography equipped with electron capture detectors, fluorescence and absorption spectroscopy. Thus, the invention also includes compounds identified as “hits” by the methods described herein, and methods for their administration and use in the treatment, prevention, or delay of development or progression of a disorder described herein.

Test compounds identified as candidate therapeutic compounds can be further screened by administration to an animal model of a disorders associated with neovascularization, as described herein. The animal can be monitored for a change in the disorder, e.g., for an improvement in a parameter of the disorder, e.g., a parameter related to clinical outcome. In some embodiments, the parameter is unwanted vascularisation, and an improvement would be a decrease in the levels of vascularisation.

One of skill in the art will appreciate that the methods described herein can be performed on non-rodent, e.g., human samples, e.g., samples obtained from human fetuses at different stages of development, as well as samples at substantially the same stage of development, but in pathological and non-pathological stages. For example, a surgical specimen from a subject with a disorder, e.g., retinopathy of prematurity or retrolental fibroplasias, can be used, and compared with a normal, unaffected control, e.g., an age-matched control.

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES Example 1 Observation of Whole-Mount Specimens

To document the changes in the hyaloid vascular system associated with development in the cornea, whole-mount specimens were observed.

A total of 44 C57BL/6 newborn male and female litters were obtained from Jackson Laboratories (Bar Harbor, Me.) were used for the experiments described herein. The age of the newborn mice was expressed in terms of post-gestational days. The newborn mice were sacrificed on post-gestational days 1, 4, 8, 16, 24, and 30 (i.e., P1, p4, p16, p24, and P30). Four eyes per each post-gestational day were used for the histological study. For the lens and vitreous protein extraction were used 20 eyes of P 1 mice, 20 eyes of P 4 mice, 12 eyes of P 8 mice and 12 eyes of P 16 mice. Each of the 12 newborn mice used for the histological study was perfused with 4% paraformaldehyde in PBS under general anesthesia administered by intramuscular injection of a mixture of ketamine (200 mg/kg) and xylazine (10 mg/kg). The eyes were removed and immerse in buffered neutral formalin solution (100 ml 40% formalin, 900 ml distilled water, 4.0 gm monobasic sodium phosphate, 6.5 gm dibasic sodium phosphate), then they were embedded into paraffin and were cut in tissue slices of 5 micron each with a microkeratome. Each sample was stained with Hematoxylin-Eosin (H-E) staining

By embryonic day 11 (E11) the hyaloid artery enters the optic cup and extends anteriorly, branching to form the vascular tunic of the lens (Smith, Systematic evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Pp 45-63. Sunders, 2002). From E14 to birthday the blood vessels that occupied most of the vitreous cavity in earlier stages have become less prominent except around the lens and along the inner retinal surface; the PM and the TVL remain prominent (Smith, Systematic evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Pp 45-63. Sunders, 2002).

PM

The PM of the newborn mice showed as a dense plexus of capillaries that began to regress on post-gestation day 4 and become vestigial on day 8. The PM disappeared completely in all eyes on day 16.

TVL

The radial branches of the TVL that lie on the lens surface are prominent until P4, particularly posterior to the lens equator. Later there is a gradual disappearance of the TVL and it is completely disappeared in about one third of eyes examined on day P24 and in all eyes on day P30.

HA and VHP

The HA arose from the optic disc as a single thick proximal trunk and entered the vitreous branching in several vessels of the VHP and running anteriorly to the posterior pole of the lens. As the whole eye developed in size and the volume of the vitreous increased, the VHP run toward the lens joining the TVL and became less prominent. Involution of HA and VHP has begun by day 1 and from day 12 to day 30 there is a gradual disappearance of those vessels.

These results concur with previous reports of HVS development and regression.

Example 2 Progressive Regression of HVS in the Mouse and Differential Protein Expression Profile

This example describes the use of a proteomic approach to try to decipher the biochemical events coexisting with the progressive regression of the HVS. The proteomic analysis provided an opportunity to compare different stages of the mouse eye development, to identify specific qualitative and quantitative protein changes, associated with the early maintenance and later regression of the HVS.

Therefore to fully characterize and analyze such a dynamic process, experiments should be performed that capture the protein expression profiles of the lens and the vitreous at the various stages of blood vessel regression.

To prepare mouse lens and vitreous for 2-D electrophoresis, 32 newborn mice were decapitated. The eyes were enucleated and then frozen at −80 degrees Celsius. The frozen eyes were scraped with a blade to remove cornea, aqueous humor, conjunctiva, sclera, iris, ciliary body, uvea and retina and to obtain the lens surrounded by PM and TVL and the primary vitreous containing VHP.

The scraping was done on a dry-ice bed to prevent the specimen from warming up and the consequent protein denaturation, melting of the tissue and contamination of the specimen by eye components different from lens and primary vitreous.

Twenty specimens of P1, 20 specimens of P4, 12 specimens of P8, and 12 specimens of P16 were independently solubilized in 250 μl of Total Protein Extraction Buffer (7 M urea, 2 M thiourea, 1% (w/v) ASB-14 detergent, 40 mM Tris base, 0.001% bromophenol blue, 20% carrier ampholyte; Biorad Laboratories, Hercules, Calif.) plus 2 μl of 200 mM tributylphosphine by mechanically homogenizing them with an electrical tissue homogenizer for 5 minutes, in an ice-water bath to prevent the specimens from warming up.

The homogenate was transferred into 1.5 ml micro centrifuge tubes and the protein extracts were cleared by centrifugation at 14,000 rpm for 20 minutes at 4° Celsius to remove particulates. The protein concentration of the cleared supernatants was determined by using a compatible protein assay (Biorad Laboratories, Hercules, Calif.), and samples were stored at −80° Celsius until use.

Three separate experiments were performed.

I. Differential Protein Expression in P1, P4, P8, P16 using IPG Strips pH 3-10

A time course experiment was designed to examine the changes in protein expression at the critical time points throughout the HVS regression process.

Lens and vitreous of P1, P4, P8 and P16 were selected to perform the experiment because the histological analysis showed that in post-gestation day 1 the hyaloid network is still prominent and by post-gestational day 16 the hyaloid network is already vestigial. In this experiment, three samples per each post-gestational day were loaded onto nonlinear immobilized pH gradient (IPG) gel strips (7 cm, pH 3-10) and rehydrated overnight with Rehydration/Sample Buffer (Biorad Laboratories, Hercules, Calif.).

As this is the first reported application of proteome analysis on HVS regression, several of the conditions for tissue selection and preparation were developed and optimized to obtain clean specimen of lens and vitreous to avoid the presence of proteins coming from other part of the eye on the final 2-DE gels.

Images of the 2-DE gels were captured with Molecular Imager FX Pro Plus multi-imager system and protein expression profile at each time point was compared in triplicate using the Phoretix 2D imaging analysis software.

Protein spots that were reproducibly differentially expressed in P1 and P 16 were considered for protein identification. The statistical significance of changes was evaluated using the Phoretix 2D software.

Gel bands were excised and minced into approximate 1 mm³ pieces with a sterile razor blade of the Xcise technology platform from Proteome system and placed into a sterile microcentrifuge. Gel pieces were destained 3 times by adding 200 uL of 25 mM NH₄HCO₃ in 50% acetonitrile, dried using a SpeedVac® concentrator, alkylated and digested with trypsin (Promega, Madison, Wis., USA) in 50 mM of ammonium bicarbonate overnight to release tryptic peptides. Samples were dried in a SpeedVac® to remove residual ammonium bicarbonate. Peptides were resuspended in 50% acetonitrile with 1% formic acid solution. About 30% of the digest was subjected to nano-LC ESI IT MS/MS analysis.

A Surveyor LC pump (ThermoElectron, CA) with a C18 trapping column (300 um i.d.×1 mm, Dionex, CA) and a self-packed reversed-phase column 75 mm i.d.×15 cm (Magic C18AQ, 3 um) was used for nano-LC experiments. An LCQ Deca XP Plus ESI mass spectrometer (Thermo Electron, CA) was used for all the experiments. In data-dependent MS/MS scanning, a full MS scan between 400 and 2000 m/z was followed by five full MS/MS scans for the five most intense ions from the MS scan in all ESI. MS/MS data-dependent acquisition, followed by database searching with SEQUEST (BioWorks 3.1, ThermoElectron) allowed protein identification.

Fully tryptic peptides were matched with SEQUEST at a delta correlation ( )Cn) of greater than 0.08 and correlation (Xcorr) greater than 1.9, 2.2 and 3.5 for charged states of +1, +2 and +3, respectively. The search was performed against the whole NCBInr mouse protein sequence database, and human homologs (e.g., proteins with at least 75% identity to the mouse sequence) were identified (www.ncbi.nml.nih.gov).

Protein expression maps were generated in triplicate per each time point obtaining a reproducible separation of the protein spots on the 2-DE gels. On average, up to 1300 proteins spots could be detected in each gel with the Phoretix 2D imaging analysis software. This software provides the ability to “warp” different gel images using mathematical algorithms, improving the quality of the protein spot matching between the gels and allowing easy detection of the differences among the gels.

The 2-DE gels demonstrated a progressive lessening in the number and in the intensity of the protein spots from P1 to P16, particularly of the proteins that migrated in the area corresponding to pI 4 to pI 7 and M_(r) 30 kDa to 90 kDa. However, the warping of P1, P4 and P8 with P16 revealed the presence of 20 protein spots in P16 that are not present in the other gels.

This evidence suggest the presence in the earlier post-gestation days of an active protein expression coexisting with the presence of a prominent HVS and the presence in P16 of factors whose synthesis or degradation is related to the regression of the HVS itself.

For this initial study, 11 protein spots were identified, using the Phoretix 2D imaging analysis software, that were present in P1 at greater than two-fold higher levels of expression relative to P16 were selected and excised for identification. From these 11 spots, 23 differentially expressed proteins were identified (Table 1); one of them is an unnamed protein product and two of them (the serotransferrin precursor and similar to ethanol induced 6) were identified in multiple spots, as they are post-translationally modified versions of the same protein.

TABLE 1 Proteins Present in P1 at >2X levels of expression in P16 HUMAN MOUSE HOMOLOG GENE GENE # PROTEIN BANK # BANK # 1. alpha fetoprotein 31982513 120042 2. Calmodulin 115512 56404656 3. protein product 19263784 19263784 (—) 4. Creatine kinase 15929689 34335231 5. dermatan-4-sulfotransferase-1 31980715 18497304 6. Ethanol induced 6 homolog 38082607 (—) 7. GRP1 (general receptor for 31980946 32171221 phosphoinositides 1) 8. heterogeneous nuclear ribonucleoprotein K 38074994 51464712 homolog 9. histidine triad nucleotide binding protein 33468857 21359982 10. immunoglobulin 9E10 heavy chain 2505942 (—) 11. KH-type splicing regulatory protein 38082738 4808586 12. Profilin 1 12846944 4826898 13. prolyl 4-hydroxylase, beta polypeptide 20913929 20070125 14. protein 40 kD homolog 38079048 51460993 15. protein product 33115175 33115175 (—) 16. protein product 12845853 12845853 (—) 17. RAD23a homolog 38089412 (—) 18. Ribosomal protein S12 17390846 (—) 19. ring finger and WD repeat domain 1 24418905 50233824 20. Serotransferrin precursor 21363012 136191 21. Synovial sarcoma, X breakpoint 2 21594537 41281571 interacting protein 22. Trk-fused gene 19353070 21361320 23. Tumor rejection antigen gp96 15030324 4507677

All 20 of the spots differentially expressed in P16, i.e., present in P16 at greater than two-fold higher levels of expression relative to P1 were excised and identified. From these 20 spots, 39 differentially expressed proteins were identified (Table 2); four of them are unnamed protein products and eight of them (Crybbl protein, fatty acid binding protein 5, crystallin α1, crystallin βA1, crystallin βA4, crystallin βB3, crystalline γb, and crystalline γd) were identified in different spots, as they represented modified versions or fragments of the same protein.

TABLE 2 Proteins Present in P16 at >2X levels of expression in P1 HUMAN MOUSE HOMOLOG GENE GENE # PROTEIN BANK # BANK # 1. protein product 38089687 38089687 (—) 2. Acvrl1 protein (ALK1) 15929282 4557243 3. Albumin 1 19353306 8392890 4. Alpha enolase 13637776 4433141 5. Cathepsin 3 precursor 19424144 (—) 6. Cofilin 1 37194891 5031635 7. Crybb1 protein 22137737 47678381 8. Crystallin, alpha A 30794510 (—) 9. Crystallin, beta A1 20304089 12056461 10. Crystallin, beta A2 31088965 13623372 11. Crystallin, beta A4 33989574 4503059 12. Crystallin, beta B2 6681035 4503063 13. Crystallin, beta B3 37589234 4758074 14. Crystallin, gamma B 38049551 4885157 15. Crystallin, gamma C 33990600 10518338 16. Crystallin, gamma D 34784220 13377002 17. Crystallin, gamma F 33991687 (—) 18. Cytochrome P450 2D9 homolog 38077646 (—) 19. Enolase 3 15488630 16554592 20. Fatty acid binding protein 5 6754450 30583736 21. FX3B_MOUSE F-box/LRR-repeat 37537783 (—) protein 3B 22. Glyceraldehyde-3-phosphate 6679939 19924131 dehydrogenase 23. Guanine nucleotide-binding protein 15341782 20357526 24. Heat shock 70 kD protein 5 29748016 24234686 25. Heat shock cognate 71 kDa protein 123651 123648 26. Hspb1 protein 17390597 4504517 27. IgM heavy chain 1763745 54780866 28. keratin 5b homolog 38077186 (—) 29. keratin complex 2, basic, gene 5 20911031 (—) 30. Knsl7 protein 38173736 9910266 31. protein product mKIAA0585 protein 28972291 (—) 32. protein product mKIAA0650 protein 37360026 (—) 33. protein kinase, cAMP dependent 31543509 38257138 regulatory 34. protein product 1333921 1333921 (—) 35. protein product 26335149 26335149 (—) 36. RAD50 homolog 6679609 19924130 37. Solute carrier family 20 28204938 58761541 38. Tubulin 33416314 34784746 39. Vimentin 31982755 57471648 II. Differential Protein Expression in P4 and P16 using IPG strips pH 4-7,5-8, 7-10

The use of broad range strips allows the display of the most proteins in a single gel. With narrow-range and micro-range overlapping gradient strips, resolution is increased by expanding a small pH range across the entire width of a gel and more spots can be displayed per each sample. This is due to the extra resolving power from use of a narrower pI range per gel. Because proteins outside of the pH range of the strip are excluded, more total protein mass can be loaded per strip, allowing more proteins to be detectable.

In this experiment, three samples for P4 and three samples for P16 were loaded onto nonlinear immobilized pH gradient (IPG) 7 cm gel strips with pH 4-7, pH 5-8, pH 7-10 and rehydrated overnight with Rehydration/Sample Buffer. Isoelectric focusing (IEF) was performed with a programmed voltage gradient at 8,000 V for 5 hours.

IPG strips were prepared for the second dimension by two sequential 10 minute incubations in 6 M urea, 50 mM Tris (pH 8.8), 30% glycerol, 2% SDS, and 0.001% bromophenol blue, containing, alternately, 2% DTT or 2.5% iodoacetamide.

Following equilibration, second-dimension separation was then performed on 4-20% SDS-PAGE gels (Biorad Laboratories, Hercules Calif.) with the first-dimension IPG strip embedded in 0.5% agarose at the top. Proteins on gel were fixed in 10% acetic acid and 20% methanol for 1 hour and were then stained using SYPRO Rubin Protein Gel stain (Biorad Laboratories, Hercules Calif.). In total, 12 gels with samples were prepared and subjected to analysis for the first experiment and 6 for the second experiment.

Using the Phoretix 2D imaging analysis software, the gels were warped the P4 map was matched with the P16 map to compare and identify proteins that were differentially expression in these gels. Of the proteins with differential expression, a number of spots were selected.

Comparing P4 map pH 4-7 with P16 map pH 4-7, fifteen spots were selected that included proteins that were differentially expressed found to be clearly present in P4 and barely detectable or not detectable in P16, and another fifteen spots that were clearly present in P16 and barely detectable or not detectable in P1.

Comparing P4 map pH 5-8 with P16 map pH 5-8, three spots were found to be clearly present in P4 and barely detectable or not detectable in P16, and another seven spots were clearly present in P16 and not in P4.

Comparing P4 map pH 7-10 with P16 map pH 7-10, two spots were found to be clearly present in P4 and barely detectable or not detectable in P16, and another two spots were clearly present in P16 and barely detectable or not detectable in P4.

These 44 spots were identified using mass spectrometry analysis. The results are shown in Tables 3-4. Table 3 lists proteins that were identified as particularly interesting targets, due to their known function.

TABLE 3 Potentially Relevant Proteins HUMAN HOMOLOG MOUSE GENE GENE # PROTEIN BANK #GI BANK #GI 1. protein BC031593 protein 17512384 (—) 2. protein Ppp3cc 12853166 13937367 3. 14-3-3 PROTEIN TAU homolog 12849349 (—) (14-3-3 PROTEIN THETA) 4. 143B_MOUSE 14-3-3 protein 3065924 (—) beta/alpha 5. 143G_HUMAN 14-3-3 protein 3065928 (—) gamma 6. acid phosphatase 2, lysosomal 29150253 4557010 7. Acvr1 protein 15929282 4557243 8. annexin A5; annexin V 6753060 4502107 9. Ca<2+>dependent activator 6753238 34452715 protein for secretion 10. calcium binding protein 2639022 7656952 11. Calnexin 56206506 10716563 12. cathepsin 3 precursor 19424144 (—) 13. Cathepsin D 26101892 4503143 14. protein AY100450; WFIKKN- 32451494 (—) like; growth and differentiation factor 15. Cofilin 1 37194891 5031635 16. Creatine kinase, brain 10946574 (—) 17. Cttn protein 15030315 21707902 18. development- and differentiation- 51827426 (—) enhancing factor 2; PYK2 C homolog 19. DiGeorge syndrome critical region 29144908 (—) gene 6 product homolog 20. drebrin 1; drebrin E2; drebrin A 34328251 18426915 21. fatty acid binding protein 5, 6754450 4503491 epidermal 22. Fbxo9 protein 18044861 53692184 23. fibroblast growth factor 22 12843402 120050 24. FK10_MOUSE FK506 binding 26105984 7706131 protein 10 precursor 25. golgi associated, gamma adaptin 22122347 48527954 ear containing, ARF binding protein 1 26. GRP1 (general receptor for 26094386 32171221 phosphoinositides 1)-associated scaffold protein 27. H2-T10 protein 18257363 (—) 28. Hepatoma-derived growth factor 34787412 55960780 29. Inner centromere protein 26353663 51471706 30. integrin beta 2; integrin beta 2 26353439 4557886 (Cd18); Mac-1 beta; macrophage antigen 31. Male-specific lethal-3 homolog 1 11545735 5052315 32. Map3k4 protein 37590139 57338496 33. Myristoylated alanine rich protein 6678768 57870608 kinase C substrate 34. NRCA_MOUSE Neuronal cell 26333200 (—) adhesion molecule precursor (Nr- CAM) (NgCAM-related 35. PDZ domain containing homolog 26325701 58533161 36. phosducin homolog 7684610 9943842 37. Profilin 1 12846944 4826898 38. protein 1200008A14 12835962 (—) 39. protein 2310057D15Rik 12845067 (—) 40. protein 2610111M03Rik 12848227 (—) 41. protein 2700081O15Rik 26083118 (—) 42. protein A830054M12 26090077 (—) 43. protein AI507495 47523976 (—) 44. protein AI663987 51708226 (—) 45. protein AU042671 18044599 (—) 46. protein BC037006 protein 17160955 (—) 47. protein kinase, cAMP dependent 15030299 1346362 regulatory, type I beta 48. protein mKIAA0585 protein 28972291 (—) 49. protein mKIAA0650 12855134 (—) 50. protein mKIAA1565 26349512 (—) 51. protein NUF2R 12963617 12667401 52. protein phosphatase 1, regulatory 12832826 (—) (inhibitor) subunit 2 homolog 53. Protein phosphatase 2, regulatory 37718993 5453952 subunit B (B56), beta isoform 54. protein Prkcsh 14602601 15488917 55. protein putative 40-2-3 protein 26346029 15216162 56. protein Rbbp6 protein 30851332 49522749 57. protein tyrosine phosphatase, 25092609 2842713 receptor type, S 58. Ras-GTPase-activating protein 56800092 54695638 SH3-domain binding protein 59. SH3-domain GRB2 homolog 31560792 55661111 60. S-phase kinase-associated protein 31560543 (—) 1A 61. Tnf receptor-associated factor 3 6755865 22027620 62. Tnks protein 34980999 (—) 63. Tripartite motif protein 28 59807693 3183179 64. Trk-fused gene 19353070 21361320 65. Ubiquilin 2 34328236 17426453 66. ubiquitin-like 1 (sentrin) activating 7709986 (—) enzyme E1B; anthracycline- associated 67. Valosin containing protein 30023842 55662798 68. zinc finger protein 120 isoform 2 31044493 (—) 69. zinc finger protein 462; gene trap 26327260 8036504 insertion site 4-2 70. Zyx protein 32451799 33870614 71. GRP1 (general receptor for 28277382 phosphoinositides 1)-associated scaffold 72. otoferlin [Mus musculus] 51831108 73. Cofilin 1, non-muscle [Mus 28374265 musculus] 74. cathepsin 3 precursor [Mus 31560606 musculus] 75. Heat shock 70 kD protein 5 31981721 (glucose-regulated protein) [Mus musculus] 76. Acvrl1 protein [Mus musculus] 6752957 77. Tnf receptor-associated factor 3 6755864 [Mus musculus] 78. integrin alpha 2; integrin alpha 2 41054730 (Cd49b); VLA-2 receptor, alpha 2 79. H2-T10 protein [Mus musculus] 51770266 80. fibrillin-1 precursor - mouse 6755774 81. protein tyrosine phosphatase, 33286922 receptor type, S [Mus musculus] 82. transient receptor potential cation 59889895 channel, subfamily M, member 3 83. calcium channel, voltage- 51712446 dependent, L type, alpha 1S subunit 84. Krt1-15 protein 6680601 85. stress-induced phosphoprotein 1; 14389430 stress-inducible protein; IEF SSP 352 86. Hepatoma-derived growth factor 31560690 87. Lmnb1 protein 6754555 88. Myristoylated alanine rich protein 6678767 kinase C substrate 89. phosphoglycerate kinase 30802044 90. acetyl-Coenzyme A 31542049 acetyltransferase 1

Table 4 is a list of those proteins with unknown function that are differentially expressed during development of the HVS.

TABLE 4 Differentially Expressed Unknown Proteins MOUSE GENE BANK SIGNIFICANT Possible function # PROTEIN #GI HOMOLOGY with (by homology) 1. protein 4930477M19 29244200 solute carrier family 22 2. protein XP_358378 38089454 LOC348180 protein 3. protein XP_148779 38082098 unknown 4. protein 4732456N10 29244176 keratin 5 5. protein D630003M21 29244074 KIAA1755 protein homolog 6. protein MGC11770 21450213 alanyl-tRNA synthetase homolog 7. protein 4832416E03 27370264 alanyl-tRNA synthetase homolog 8. protein S25715 284778 unknown protein—mouse 9. protein 4932412H11 27370338 leucine-rich repeat containing protein homolog 10. protein product 26390223 protein disulfide 26390223 isomerase homolog 11. protein product 26351281 Titin homolog 26351281 12. protein product 1333921 crystallin, gamma A 1333921 13. protein product 26354026 tropomyosin 3 26354026 14. protein product 26338367 unknown 26338367 15. protein product 26329025 unknown 26329025 16. protein product 12852979 PDZ domain 12852979 containing 1 17. protein product 26325560 unknown 26325560 18. protein product 26354901 ankyrin homolog 26354901 19. protein product 26340818 unknown 26340818 20. protein product 26346649 tropomyosin 1 26346649 21. protein product 26346108 Interferon-induced 26346108 protein 22. protein product 26335149 endothelial progenitor 26335149 cells, angiopoietin homolog 23. protein product 38257031 oogenesin 1 38257031 24. protein product 26342222 High mobility group 26342222 homolog 25. protein product 26351025 unknown 26351025 26. protein for 38328278 heterogeneous nuclear MGC: 70225 ribonucleoprotein A3 27. protein for 38328232 unknown MGC: 69648 28. protein for 32451767 Snx25 protein MGC: 65613 29. protein for 38328220 septin 11 MGC: 70304 30. protein for 38348540 unknown MGC: 66590 31. protein for 38174349 T-complex protein 10c MGC: 74310 32. protein for 38173718 nestin homolog MGC: 66854 33. cDNA 4930513F16 29789229 IQ calmodulin-binding motif containing protein 34. cDNA 1110021E09 30354152 unknown 35. cDNA 4930578C19 30424860 nucleotide apoptosis triphosphate hydrolases 36. cDNA 6030404K05 30425216 C2H2 zinc-finger at its gene N-terminal region 37. cDNA C730025I08 30425272 RETINOL gene DEHYDROGENASE 38. cDNA 2610019P18 30519939 unknown 39. cDNA C730027J19 30520215 rat hypertension- gene associated homolog 40. cDNA 2610036L13 31127295 cell division cycle angiogenesis associated 5 41. cDNA 5730444A13 31542010 G-protein beta WD-40 apoptosis repeats 42. cDNA 5230400J09 33859785 duf containing peotein, zeta-crystallin 43. cDNA 1500011H22 34784371 unknown 44. cDNA 9030623C06 34980904 keratin 21, type I, cytoskeletal 45. cDNA 6430598A04 34980939 netrin-G1 ligand apoptosis gene NGL-1 46. cDNA 1500031K13 37589970 calcium binding protein 39-like 47. cDNA 3110001E11 38075065 unknown 48. cDNA 1700020H17 38075351 molybdopterin synthase sulfurylase 49. cDNA 4933432B09 38077919 unknown 50. cDNA 1110037F02 38078070 unknown 51. cDNA 5730537H01 38084391 mRNA-decapping enzyme (DCP2) 52. cDNA E330005F07 38089151 microtubule binding gene protein hook3, GTPase 53. cDNA B630009I04 38090459 activating signal cointegrator 1 complex 54. cDNA 9130006A14 38091346 Mus musculus proliferation RasGEF domain and apoptosis family, Cell Division Control Protein 25 55. cDNA F830010I22 38091563 TENSIN homolog 56. cDNA A930040G15 46048307 unknown 57. cDNA 4432411E13 51769098 hyperplastic discs protein, tumor suppressor 58. cDNA C130068M19 59858553 beta WD-40 repeats containing protein Differential Protein Expression in P1, P4, P8, P16 using IPG Strips pH 3-10 and Phosphostaining

In this experiment, two samples per each post-gestational day were loaded onto nonlinear immobilized pH gradient (IPG) gel strips (7 cm, pH 3-10) and rehydrated overnight with Rehydration/Sample Buffer (Biorad Laboratories, Hercules, Calif.). The same steps were followed for the gel electrophoresis, and then proteins on gel were fixed in 10% acetic acid and 20% methanol overnight. Each of the 8 gels was incubated three times for 10 minutes with 100 mL of dH₂O with gentle agitation in order to remove all of the methanol and acetic acid from the gel.

Then each gel was incubated in the dark in 50 mL of Pro-Q® Diamond phosphoprotein gel stain with gentle agitation for 75-120 minutes (Molecular Probes Laboratories); each gel was destained for two times in 80-100 mL of Destain Solution (Molecular Probes Laboratories) at room temperature, protected from light. Images of each gel were taken with the Image acquisition system Molecular Imager FX Pro Plus. Every gel was then stained for three hours with SYPRO Rubin Protein gel Stain (Biorad Laboratories, Hercules Calif.), and proteins on the gel were fixed twice in 10% acetic acid and 20% methanol for 1 hour. Images of each gel were taken with the Image acquisition system Molecular Imager FX Pro Plus.

The proprietary fluorescent stain of Pro-Q® Diamond phosphoprotein gel staining (Molecular Probes Laboratories) allows direct in-gel detection of phosphate groups attached to tyrosine, serine or threonine residues. The comparison between the images obtained from P1 and P16 gels stained with the phosphostain showed a different pattern of protein activation. Thirteen protein spot were identified with mass spectroscopy that were present in P1 but not in P16, and nine protein spots present in P16 but not in P1. Proteins identified by this method are listed in Table 5.

TABLE 5 PROTEINS WITH ALTERATIONS IN PHOSPHORYLATION HUMAN MOUSE PROTEIN GI # GI# 1810015P09Rik protein 21411262 2610111M03Rik protein 19353142 a disintegrin and metalloprotease domain 4; 27923590 a disintegrin and metallop Albumin 1 19353306 alpha fetoprotein; alpha-foetoprotein 31982513 antibody heavy chain variable region 1518293 B230317C12Rik protein 37994630 Ca²⁺dependent activator protein for 6753238 secretion Calnexin 25955477 CRAA_MOUSE Alpha crystallin A chain, 117369 major component Cryab protein 14789702 Crybb1 protein 22137737 crystallin, alpha A; lens opacity 18; 30794510 crystallin, alpha 1; alpha-A-cry crystallin, beta A1 20304089 Crystallin, beta A2 31088965 Crystallin, beta B3 37589234 crystallin, gamma B 38049551 Crystallin, gamma C 33990600 Crystallin, gamma D 34784220 Crystallin, gamma F 33991687 Crystallin, gamma S 46854370 or 33989585 47124529 drebrin 1; drebrin E2; drebrin A 34328251 dynein, axonemal, heavy polypeptide 9 38091406 Facl6 protein 16359313 gamma 4-crystallin 51017 Heat shock 70 kD protein 5 (glucose- 29748016 regulated protein) Heat shock protein 1, alpha 28436908 heat shock protein 1, beta; heat shock 6680305 protein, 84 kDa 1; heat shock 90 heat shock protein, 110 kDa 13278232 Hook homolog 1 38197327 HS7C_MOUSE Heat shock cognate 71 kDa 123651 protein Hspcb protein 29612561 hypothetical protein 4732456N10 29244176 IgM heavy chain 1763745 integrin alpha 2; integrin alpha 2 (Cd49b); 6680478 VLA-2 receptor, alpha 2 sub laminin, beta 2; Laminin S 31982223 laminin, gamma 2; nicein, 100 kD; nicein, 19115956 100 kDa Lmnb1 protein 34849832 mannosidase 2, alpha 2; alpha mannosidase 51477716 27777691 IIx; mannosidase, alpha, cla mKIAA0723 protein 37360062 mutS homolog 5 7305281 Myristoylated alanine rich protein kinase C 28302374 substrate Nasp protein 13435642 nuclear autoantigenic sperm protein 13384598 Pleckstrin homology-like domain, family 17512344 A, member 2 prolactin-like protein E; prolactin-like 6679471 protein G protein tyrosine phosphatase, receptor 25092609 type, S PSD3_MOUSE 26S proteasome non-ATPase regulatory 19856169 subunit 3 (26S proteasome reg Rbbp6 protein 30851332 Ribosomal protein S27a 12805285 RIKEN cDNA 0610041L09 21313618 RIKEN cDNA 1500011H22 34784371 RIKEN cDNA 1700028P14 29436989 RIKEN cDNA 3000003F02 27369583 RIKEN cDNA 4432411E13 38077035 RIKEN cDNA 6030404K05 gene 30425216 RIKEN cDNA A030005L19 13386450 RIKEN cDNA D430026P16 gene 28893017 RIKEN cDNA F830010I22 gene 38091563 S25715 hypothetical protein - mouse 284778 (fragment) Serine (or cysteine) proteinase inhibitor, 19343549 clade A, member 1b [Mus muscu Serine (or cysteine) proteinase inhibitor, 38174657 clade A, member 1e [Mus muscu Serpina 1b protein 15277553 similar to 60S ribosomal protein L10 (QM 38079574 protein homolog) [Mus musculu similar to alpha-2-HS-glycoprotein 38080571 homolog - mouse similar to alpha-tubulin 38050521 similar to ATP-binding cassette, sub-family 38049559 A, member 12 isoform b [Mu similar to Crybb1 protein 38074960 similar to Elongation factor 1-alpha 1 (EF- 38090266 1-alpha-1) (Elongation fact similar to heat shock protein hsp90 beta 38096689 similar to hypothetical protein FLJ21665 38074149 similar to K-ALPHA-1 protein 38084290 Similar to neuronal protein 28175466 similar to tubulin Mbeta 1 38075765 similar to tubulin, beta 3 38085389 Solute carrier family 3, member 1 18490867 15488595 S-phase kinase-associated protein 1A 12805297 Synovial sarcoma, X breakpoint 2 21594537 interacting protein Tnks protein 34980999 Tripartite motif protein 28 37231553 trypsinogen 10 2358087 trypsinogen 16 16716569 Tubulin, alpha 2 12805487 Tubulin, alpha 6 20071240 tubulin, beta 21746161 Tubulin, beta 2 33416314 Tubulin, beta 3 21595026 Tubulin, beta 4 32766247 Tubulin, beta 5 13277909 ubiquitin specific protease 9, Y 22507351 chromosome ubiquitin-like 1 (sentrin) activating enzyme 7709986 E1B; anthracycline-associa Unknown (protein for MGC: 69991) 38328337 unnamed protein product 1333921 Valosin containing protein 29144989 vimentin 57471648 31982755 ZIN_MOUSE Striatin 4 (Zinedin) 17367523 1012270B antibody L-V, anti-arsonate GI: 224215 2700081O15Rik protein 37589581 5730509E04Rik protein 20071529 Actin-like 6 29436558 arylalkylamine N-acetyltransferase 6752938 ATPase, H+ transporting, V1 subunit A, 31560731 isoform 1; ATPase, H+ transport beaded filament structural protein 2, 38090061 phakinin Cathepsin D 21450788 CRAA_MOUSE Alpha crystallin A chain, 117369 major component Creatine kinase, brain 15929689 Cryab protein 14789702 Crybb1 protein 22137737 crystallin, alpha A; lens opacity 18; 30794510 crystallin, alpha 1; alpha-A-cry crystallin, beta A1 20304089 Crystallin, beta A2 31088965 Crystallin, beta A4 33989574 crystallin, beta B2; betaB2-crystallin; 6681035 Philly cataract Crystallin, beta B3 37589234 crystallin, gamma B 38049551 Crystallin, gamma C 33990600 Crystallin, gamma D 34784220 Crystallin, gamma F 33991687 crystallin, gamma N 23346485 Crystallin, gamma S 33989585 eukaryotic translation initiation factor 3, 21313620 subunit 5 (epsilon) [Mus m G protein-coupled receptor 106; G protein 15546059 coupled receptor affecting t gamma 4-crystallin 51017 Hnrpk protein 13879427 HS7C_MOUSE Heat shock cognate 71 kDa 123651 protein hypothetical protein 4932412H11 26325921 integrin alpha 2; integrin alpha 2 (Cd49b); 6680478 VLA-2 receptor, alpha 2 sub kinase D-interacting substance of 220 kDa 38049418 Kinesin-like 6 13905108 laminin, beta 2; Laminin S 31982223 Map3k4 protein 37590139 mKIAA1565 protein 37360452 Nitrogen fixation cluster-like 29476869 olfactory receptor GA_x6K02T2PBJ9- 32057602 6773690-6774628 phakinin, CP49 17977856 PSD3_MOUSE 26S proteasome non-ATPase regulatory 19856169 subunit 3 (26S proteasome reg RIKEN cDNA 4833420I20 17390408 RIKEN cDNA 4930578C19 30424860 RIKEN cDNA 4933424A10 gene 28893379 RIKEN cDNA 6030404K05 gene 30425216 RIKEN cDNA 9030623C06 34980904 RIKEN cDNA A030005L19 13386450 RIKEN cDNA A930040G15 19527136 RIKEN cDNA C130068M19 gene 38073604 RIKEN cDNA C730027J19 gene 30520215 RIKEN cDNA F830010I22 gene 38091563 Sema domain, immunoglobulin domain 37046950 (Ig), and GPI membrane anchor, (semap SH3-domain GRB2-like 2 17390906 similar to 14-3-3 protein sigma 38089318 similar to actin, gamma, cytoplasmic 38089775 similar to cytoplasmic beta-actin 38089227 similar to fibrous sheath-interacting protein 2 38074908 similar to integrin alpha 6 38090030 similar to ribosomal protein L31 38085230 solute carrier family 6 (neurotransmitter 19527208 transporter, creatine), memb T-box 1 20891977 trypsinogen 16 16716569 Tubulin, alpha 2 12805487 uncoupling protein 2, mitochondrial 31543920 Unknown (protein for MGC: 66590) 38348540 Unknown (protein for MGC: 69991) 38328337 Unknown (protein for MGC: 74310) 38174349 unnamed protein product 26335149 unnamed protein product 1333921 unnamed protein product 26351281 unnamed protein product 1333921

Example 2 Differential Expression of Activin Receptor-Like Kinase 1 (ALK1)

The activin receptor-like kinase 1 (ALK1), a TGF-beta1 type I receptor, plays an inhibitory role in angiogenesis and vascular development. Mutations of ALK1 gene are linked to human type II hereditary hemorrhagic telangiectasia. Our purpose was to develop a mouse model to study the differential expression of proteins during the phase of Hyaloid Vascular System (HVS) regression and determine the role of ALK1 in this model.

Materials and Methods: Thirty-two newborn C57BL/6 mice were sacrificed on post-gestational days 1 (n=20 eyes), 4 (n=20 eyes), 8 (n=12 eyes), and 16 (n=12 eyes). The lens, the Pupillary Membrane (PM), the Tunica Vasculosa Lentis (TVL) and the primary vitreous containing the Vasa Hyaloidea Propria (VHP) were isolated. Proteins were extracted from each specimen, loaded onto nonlinear immobilized pH gradient (IPG) gel strips, and separated by isoelectric points and molecular weights. Protein expression profile at each time point was compared using the Phoretix 2D image analysis software. Proteins from differentially expressed protein spots were isolated and identified using Mass Spectrometry (MS). Immunohistochemistry was performed to determine the expression of ALK1 during the HVS regression phase.

Results: The generated protein expression maps showed reproducible separation of the protein spots on the 2 Dimension Electrophoresis gels. Up to 1400 proteins spots were detected per gel. Progressive decrease in the number and intensity of the protein spots occurred from P1 to P16, particularly in the area corresponding to pI 4-7 and M_(r) 30-90 kDa. Twenty protein spots in the P16 gels were not present in the P1 gels.

MS revealed 39 differentially expressed proteins (PP 16-1 to 39) in the P16 specimens (Table 1). ALK1 was identified as PP16-31 (spot n° 17). The warping of P16 with P1, P4 and P8 showed the presence of this spot only in P4 and P8. Immuno-histochemistry of the cornea, PM, and TVL using anti ALK1 antibody confirmed the presence of ALK1 in the TVL at P4 and P16.

Conclusion: The synthesis or degradation of one or more proteins, present at P16 (PP16-1 to 39), may be related to the regression of HVS in the mouse. Identification of ALK1 by proteomic analysis and immunohistochemistry in this model suggests that the TGF-beta1 pathway may be involved in this process.

Example 3 Progressive Regression of HVS in the Mouse and the Differential Protein Expression Profile

A time course experiment was designed to examine the changes in protein expression at P1 and P16 throughout the HVS regression process. As this is the first reported application of proteomic analysis on HVS regression, several conditions for tissue selection and preparation were developed and optimized to obtain clean specimens of the lens and vitreous for 2-DE gels.

Mouse Anterior Tissue Preparation for 2-DE Gels

For the protein extraction and ALK1 immunolocalization studies, newborn mice were sacrificed on post-natal days 1, 4 and 16. Using a dry ice bed, frozen mouse eyes were scraped with a blade (Beaver #15) to remove the cornea, conjunctiva, sclera, ciliary body, uvea, and retina, leaving the lens surrounded by the PM, TVL, and primary vitreous (containing VHP). The dry ice bed was used to prevent warming of the specimen, tissue melting, and subsequent protein denaturation. Samples of P1, P4 and P16 were pooled and independently solubilized in 250 μl of total protein extraction buffer 7 M urea, 2 M thiourea, 1% (w/v) ASB-14 detergent, 40 mM Tris base, 0.001% bromophenol blue, 20% carrier ampholyte (Biorad Laboratories, Hercules, Calif.) and 2 μl of 200 mM tributylphosphine by mechanically homogenizing them with an electrical tissue homogenizer for 5 min on ice. The homogenates of the protein extracts were cleared by centrifugation for 20 min at 14,000 rpm and 4° C. to remove particulates. Protein concentration of the supernatants was determined by protein assay (Biorad Laboratories).

Two-Dimensional Electrophoresis, Image Analysis and Protein Identification

Three samples per each post-gestational day were loaded onto nonlinear, immobilized pH gradient (IPG) gel strips (7 cm, pH 3-10), subjected to isoelectric focusing with a programmed voltage gradient at 8,000 V for 5 hours, and rehydrated overnight with rehydration/sample buffer (Biorad Laboratories). IPG strips were equilibrated with buffer containing 6 M urea, 50 mM Tris (pH 8.8), 30% glycerol, 2% SDS (sodium dodecyl sulfate), and 0.001% bromophenol blue containing 2% DTT (dithiothreitol) or 2.5% iodoacetamide. Following equilibration, second-dimension separation was performed on 4-20% SDS-PAGE (SDS-polyacrylamide gel electrophoresis) gels (Biorad Laboratories) with the first-dimension IPG strip embedded in 0.5% agarose at the top. After electrophoresis, the proteins on the gel were fixed in 10% acetic acid and 20% methanol for 1 hour and then stained with SYPRO™ Ruby (Biorad Laboratories). Images of the 2-DE (two-dimensional electrophoresis) gels were captured with Molecular Imager FX Pro Plus multi-imager system and the protein expression profiles at each time point were compared, in triplicate, using the Phoretix 2D image analysis software. Protein spots present in P16 with expression level two- to ten-fold greater than P1 were considered for protein identification. The statistical significance of changes was evaluated using Phoretix 2D software.

Gel bands (differentially expressed proteins) from 2-DE gels were excised, minced into approximate 1 mm³ pieces with a sterile razor blade of the Xcise technology platform from Proteome system, alkylated, and digested with trypsin (Promega, Madison, Wis.). Peptides were resuspended in 50% acetonitrile with 1% formic acid solution and subjected to nano-LC ESI IT MS/MS analysis. A Surveyor LC pump (Thermo Electron, San Jose, Calif.) with a C18 trapping column (300 μm i.d.×1 mm, Dionex, Sunnyvale, Calif.) and a reversed-phase column 75 μm i.d.×15 cm (Magic C18AQ, 3 μm) was used for nano-LC experiments. An LCQ Deca XP plus ESI mass spectrometer (Thermo Electron, San Jose, Calif.) was used for all the experiments.

MS/MS data-dependent acquisition followed by database searching with SEQUEST (BioWorks 3.1, Thermo Electron, San Jose, Calif.) allowed protein identification. Fully tryptic peptides were matched with SEQUEST at a delta correlation (ACn) of greater than 0.08 and correlation (Xcorr) greater than 1.9, 2.2, and 3.5 for charged states of +1, +2, and +3, respectively. Peptide mass fingerprints (PMFs) were searched for matches with the virtually generated tryptic protein masses of the NCBInr mouse protein sequence database (available at ncbi.nml.nih.gov). All databases were provided in the public domain by the host institutions. Proteins were noted as differentially expressed if they could not be located at the corresponding position on the 2-DE gel of the other time point.

Protein expression maps were generated in triplicate for each time point, obtaining a reproducible separation of the protein spots on the 2-DE gels. Up to 1400 protein spots could be detected in each gel with the Phoretix 2D image analysis software (FIG. 1A). This software allows the possibility to warp different gel images to improve the quality of the protein spot matching between the gels and allow an easy detection of the differences among the gels. The 2-DE gels were analyzed, and a progressive decrease in the number and intensity of the protein spots from P1 to P16 was observed, particularly of the migrated proteins in the area corresponding to pI 4-7 and M_(w)30-90 kDa (FIG. 1B-C).

However, the warping of the 2-D gel images of P1 with P16 revealed the presence of a small number of protein spots for which expression level in P16 was two to ten-fold greater than P1. Twenty protein spots were analyzed using mass spectrometry analysis. Some of these identified proteins displayed slightly different molecular weights and pIs, suggesting the presence of different isoforms or posttranslational modifications. Eighteen differentially expressed proteins were identified; two additional proteins were unclassified and 15 were unknown. ALK1 was identified as spot #17.

TABLE 6 PROTEINS WITH DIFFERENTIAL EXPRESSION AT POST- GESTATIONAL DAY 16 HUMAN MOUSE HOMOLOG GENE GENE SPOT # PROTEIN NAME BANK # BANK # 1 RAD50 homolog 6679609 19924130 2 Olfactory receptor 32057602 41200972 GA_x6K02T2PBJ9-6773690- 6774628 3 Cofilin 1, non-muscle 28374265 116848 4 Guanine nucleotide-binding 15341782 20357526 protein, β-1 subunit 5 Protein kinase, cAMP dependent 15030299 1346362 regulatory, type I β 6 α enolase (2-phospho-D-glycerate 13637776 119339 hydro-lyase) (non-neural enolase) 7 Cathepsin 3 precursor 21450788 30582658 8 Unclassified 9 Knsl7 protein 26095143 Knsl7 10 F-box/LRR-repeat protein 3B (F- 37537783 16306584 box and leucine-rich repeat protein) 11 Enolase 3, β muscle 15488630 16554592 12 Albumin 1 19353306 113576 13 Heat shock cognate 71 kDa 123651 123648 protein 14 Fatty acid binding protein 5, 6754450 4557581 epidermal; keratinocyte lipid binding protein 15 Vimentin 31982755 57471648 16 Tubulin, β 2 33416314 4507729 17 ALK1 protein 6752957 4557243 18 CRAA_MOUSE α crystallin A 117369 1706112 chain, major component 19 Crystallin, β A4 33989574 4503059 20 Unclassified

Example 4 Immunolocalization of ALK1 in the TVL by Confocal Microscopy

To investigate whether ALK1 is expressed in TVL during mouse development, mouse eyes at P1, P4 and P16 were immunostained with anti-ALK1 antibody.

ALK1 Immunolocalization by Confocal Microscopy

Mouse eyes harvested at P1, P4, and P16 were embedded in optimal cutting temperature (OCT) compound (Miles, Elkhart, Ind.), frozen in liquid nitrogen, cryostat sectioned, and fixed in acetone for 10 min. After blocking with 1% bovine serum albumin (BSA) (Sigma Chemical Co., St. Louis, Mo.) for 30 min, the sections were incubated for 1 hour with rabbit anti-ALK1 polyclonal antibody (courtesy of Dr. D. A. Marchuck, University of North Carolina) at a concentration of 1:200. A secondary antibody used was fluorescein-conjugated, affinity-purified anti-rabbit IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, Pa.) at a concentration of 1:400. Negative controls were prepared in the same manner, with 1% BSA without primary antibody. Immunostained sections were viewed with a Leica TCS SP2 CLSM confocal laser scanning microscope (Leica, Heidelberg, Germany).

Results

The confocal immunohistochemical staining demonstrated that ALK1 is localized in the endothelial cells of the TVL at P1, P4 and P16.

Example 5 Naked pEF-ALK1 DNA Blocked bFGF Induced Corneal NV in Vivo

Naked DNA has been effectively used for the delivery of DNA into mouse corneas. To determine whether ALK1 can inhibit bFGF-induced corneal NV (neovascularization), mouse corneas were injected with naked DNAs of pEF (vector) and pEF-ALK1.

Plasmid construction and corneal naked DNA injection pYX-Asc-ALK1 cDNA was purchased from ATCC (Manassas, Va.). Plasmids were purified using a Qiagen kit (Valencia, Calif.) according to the manufacturer's instructions. The mouse ALK1 DNA was sequenced and subcloned into pEF expression vector. An Elongation Factor 1 alpha promoter (pEF; Kim et al., Gene. 1990 Jul. 16; 91(2):217-23) was used to drive the expression of the ALK1 gene. Mouse corneas received a DNA injection of 5 μA of pEF-ALK1 (400 ng/μl) or an injection of 5 μA of vector (400 ng/μl). An antibiotic ophthalmic ointment was used after surgery.

bFGF Pellet Preparation and Corneal Micropocket Assay

Pellets were made of the slow-release polymer Hydron (polyhydroxyethyl-methacrylate), which contained a combination of 45 ng/pellet of sucralfate (Sigma) and 120 ng/pellet of bFGF (R&D Systems, Minneapolis, Minn.), as previously described by Kenyon et al., Invest Ophthalmol V is Sci 37, 1625-1632 (1996).

Briefly, a suspension of sterile saline containing the appropriate amount of recombinant bFGF and sucralfate was made and concentrated using a speed-vacuum for 8 minutes. To this suspension, 10 μl of 12% Hydron in ethanol was added. The suspension was then deposited onto a sterilized nylon mesh (LAB Pak, Sefar America, Depew, N.Y.) and embedded between the fibers. The resulting grid of 10 mm×10 mm squares was allowed to dry on a sterile Petri dish for 60 min. The fibers of the mesh were pulled apart under a microscope and, among the approximately 100 pellets produced, 30 to 40 uniformly-sized pellets of 0.4×0.4×0.2 mm were selected for implantation. All procedures were performed under sterile conditions.

Three days after the naked DNA injections, corneal micropockets were created with a modified von Graefe knife in C57BL/6 mice. Hydron pellets containing 120 ng of human basic FGF were implanted into the corneal pockets.

Measurement of Corneal Neovascularization

The corneas were routinely examined and photographed in five positions: en face, superior, inferior, nasal, and temporal with a slit lamp biomicroscope (Nikon FS-2, Tokyo, Japan) on days 1, 4, 7, and 14 post-pellet implantation. The photographs were digitized and the images were resolved at 300 pixels/inch and analyzed with the NIH ImageJ image program (NIH, Bethesda, Md.). NIH ImageJ program was used to calculate the area of corneal neovascularization areas. Statistical analysis was performed with the student T-test.

Results

The ALK1 plus pellet group (FIG. 2M-P) showed no evidence of corneal NV at any time point after pellet implantation. The group receiving vector control plus pellets (FIG. 2I-L) began to develop corneal NV at day 4, and the new vessels continued to grow toward the pellet area at days 7 and 14. The area occupied by neovascularization in the ALK1 treated mice was 0.58 mm² and 0.47 mm² at days 7 and 14 after bFGF pellet implantation, respectively (FIG. 2O-P). This was significantly less than the vector treated mice 3.14 mm² (p=0.001) and 3.33 mm² (p=0.001) at 7 and 14 days after bFGF pellet implantation, respectively (FIG. 2K-L). The no-pellet control groups [ALK1 naked DNA (FIG. 2E-H) and vector naked DNA (FIG. 2A-D)] did not induce corneal NV.

These results demonstrate that injection of naked pEF-ALK1 DNA blocked bFGF induced corneal NV.

ADDITIONAL REFERENCES

-   1. Goumans and Mummery, Int. J. Dev. Biol. 44, 253-265 (2000). -   2. Goumans et al., Trends. Cardiovasc. Med. 13, 301-307 (2003). -   3. Pepper, Cytokine Growth Factor. Rev. 8, 21-43 (1997). -   4. Lamouille et al., Blood 100, 4495-4501 (2002). -   5. Roman et al., Development 129, 3009-3019 (2002). -   6. Lebrin et al., Cardiovasc. Res. 65, 599-608 (2005). -   7. Lebrin et al., EMBO. J. 23, 4018-4028 (2004). -   8. Gabison et al., Exp. Eye. Res. 78, 579-589 (2004). -   9. Murthy et al., Invest. Ophthalmol. Vis. Sci. 44, 1837-1842     (2003). -   10. Chang et al., Curr. Opin. Ophthalmol. 12, 242-249 (2001). -   11. Dawson et al., Science 285, 245-248 (1999). -   12. Chang et al., FEBS. Lett. 579, 3601-3606 (2005). -   13. Urness et al., Nat. Genet. 26, 328-331 (2000).

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. 

1. A method for identifying a candidate compound for the treatment of a disorder associated with neovascularization, the method comprising: providing a sample comprising a cell expressing activin receptor-like kinase-1 (ALK1); contacting the sample with a test compound; and monitoring expression of ALK1 in the cell, wherein a test compound that increases the expression of ALK1 is a candidate compound for the treatment of neovascularization.
 2. A method for identifying a candidate therapeutic agent for the treatment of a disorder associated with neovascularization, the method comprising: providing an animal model of the disorder; administering a candidate compound that increases the expression of activin receptor-like kinase-1 (ALK1) to the animal model; and monitoring one or more parameters of the disorder in the animal, wherein a candidate compound that improves a parameter of the disorder is a candidate therapeutic agent for the treatment of a disorder associated with neovascularization.
 3. A method of identifying a therapeutic agent for the treatment of a disorder associated with neovascularization, the method comprising: providing a subject having the disorder; administering a candidate therapeutic agent that increases the expression of activin receptor-like kinase-1 (ALK1) to the subject; and monitoring one or more parameters of the disorder in the subject, wherein a candidate therapeutic agent that improves a parameter of the disorder is a therapeutic agent for the treatment of a disorder associated with neovascularization.
 4. The method of claim 1, wherein the sample comprises cells from a human fetus.
 5. The method of claim 1, wherein the sample comprises cells from a subject having a disorder associated with blood vessel regression.
 6. The method of claim 5, wherein the disorder is retinopathy of prematurity or retrolental fibroplasia.
 7. The method of claim 1, wherein the sample comprises cells from a subject in a stage of development that is associated with vessel regression.
 8. The method of claim 7, wherein the stage is the development of the hyaloid vascular system.
 9. The method of claim 3, wherein the subject is a human subject in a clinical trial.
 10. The method of claims 1, wherein the disorder associated with neovascularization is selected from the group consisting of extraocular and ocular neovascularization.
 11. The method of claim 10, wherein the ocular neovascularization is vitreous, retinal, choroidal, or corneal neovascularization.
 12. The method of claim 1, wherein the disorder associated with neovascularization is cancer.
 13. A method for treating a disorder associated with neovascularization in a subject, the method comprising administering a therapeutically effective amount of a therapeutic composition comprising an activin receptor-like kinase-1 (ALK1) polynucleotide or polypeptide, or an active fragment thereof.
 14. The method of claim 13, wherein the composition comprises an ALK1 polypeptide comprising amino acids 22-503 of SEQ ID NO:1, or an ALK1 nucleic acid molecule comprising nucleotides 346-1791 of SEQ ID NO:2.
 15. The method of claim 13, wherein the disorder is an ophthalmological disorder associated with neovascularization.
 16. The method of claim 15, wherein the ophthalmological disorder associated with neovascularization is selected from the group consisting of eye cancer, age-related macular degeneration, retinopathy of prematurity, corneal graft rejection, glaucoma, diabetic retinopathy, wounds, age-related macular degeneration, herpetic and infectious keratitis, ocular ischemia, neovascular glaucoma, corneal, uveal and iris neovascularization, orbital and eyelid tumors, Stevens Johnson Syndrome, ocular cicatricial pemphigoid, and ocular surface diseases.
 17. The method of claim 15, wherein the ophthalmological disorder is associated with corneal, retinal, choroidal, uveal, or iris neovascularization.
 18. The method of claim 15, wherein the administering is topical or parenteral administration into the eye.
 19. The method of claim 17, wherein the administering is by local injection into or near the cornea, retina, vitreous, uvea, orbit, eyelid, conjunctiva, or iris.
 20. The method of claim 13, wherein the disorder is cancer. 